<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>182(3)</volume><submitter>Gunter SJ</submitter><journal>JAMA internal medicine</journal><pagination>342-345</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8767485</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Medicaid Spending on Drugs Marketed Without US Food and Drug Administration Approval in 2020.</pubmed_title><pmcid>PMC8767485</pmcid><pubmed_authors>Rome BN</pubmed_authors><pubmed_authors>Gunter SJ</pubmed_authors><pubmed_authors>Kesselheim AS</pubmed_authors></additional><is_claimable>false</is_claimable><name>Medicaid Spending on Drugs Marketed Without US Food and Drug Administration Approval in 2020.</name><description/><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Mar</publication><modification>2025-04-26T09:58:48.157Z</modification><creation>2025-04-06T13:10:20.905Z</creation></dates><accession>S-EPMC8767485</accession><cross_references><pubmed>35040875</pubmed><doi>10.1001/jamainternmed.2021.7614</doi></cross_references></HashMap>